18 Jul 16

The study, the potential of R788 evaluated the effect on the immune cascade in an in vivo lupus model, published in Arthritis and Rheumatism and is titled – An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival of the in Murine lupus (May 2008, Volume 58, – These results are impressive and consistent with R788 ‘s mechanism of action, said Donald G. Executive vice president and president of discovery and research at Rigel. Given this mechanism, R788 has the potential to treat a variety of immune-related disorders, of which a number are we advancing in the clinic. .

The conference will also be a series of workshops, addressing the practice-based commissioning, the future of general practice, world class commissioning urgent care, NICE and the new QOF, patient – centered NHS, will include.Reserved 2008 Quick – Med Technologies, All Rights Reserved. Nimbu and Multistat are trademarks of the Quick – Med Technologies, All other trademarks the properties of their respective owners.